In December 2013 we successfully acquired HER-Vaxx  from Biolife Science

Media Coverage

Date Title
29/11/2017

Breast Cancer Breakthrough: Australian company trials breast cancer vaccine

07/04/2017

AFR "Innovating the businesses of tomorrow" featuring Leslie Chong

07/03/2017

Imugene in the news - Imugene CEO Leslie Chong: meet the unicorn leading the cancer fight

07/03/2017

Imugene in the news - Breakthrough for local biotech as an influential backer emerges

03/09/2015

Fighting Cancer: Science and Technology Are the Key to a Cure - Massachusetts Institute of Technology Biologist Robert Horvitz discusses the fight against cancer and potential breakthroughs in treatment. He speaks with Caroline Hyde on Bloomberg Television’s “On The Move.”

23/04/2015

Life Scientist - Imugene candidate increases cancer-fighting antibodies

23/04/2015

Bionity.com article

09/04/2015

Imugene featured in Cancer Vaccine report

09/12/2014

Proactive Investors -  Imugene meets heavy demand in capital raising for HER-Vaxx

01/12/2014

Proactive Investors - HER-Vaxx peptides demonstrate high level of activity

26/08/2014

Life Scientist - Imugene names Charles Walker as CEO

16/07/2014

Life Scientist - Imugene Engages Mymetics to Manufacture
HER-Vaxx Cancer Immunotherapy

20/06/2014

Australian Financial Review Smart Investor

28/05/2014

Imugene picks peptide manufacturer for HER-Vaxx - Australian Life Scientist

24/03/2014

Proactive Investors - Imugene to be granted patent for cancer vaccine in Israel

17/03/2014

Life Scientist - Imugene kicks off IND process for HER-Vaxx

20/12/2013

Bioshares Edition 534

25/10/2013

Bioshares Edition 526

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551